New pill targets rare gene mutations in Hard-to-Treat cancers

NCT ID NCT07394374

Recruiting now Disease control Sponsor: Cullgen (Shanghai),Inc Source: ClinicalTrials.gov ↗

First seen Feb 06, 2026 · Last updated May 15, 2026 · Updated 17 times

Summary

This early-stage study tests an experimental drug, CG001419, in adults with advanced solid tumors that have specific NTRK gene changes. The goal is to find a safe dose and see if the drug can shrink tumors. About 42 participants will take the drug by mouth until their disease gets worse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanxi Provincial Cancer Hospital
RECRUITING

Taiyuan, China

Contact
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, China

Contact
The Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Sir Run Run Shaw Hospital, Affiliated to Zhejiang University School of Medicine
RECRUITING

Hangzhou, China

Contact
West China Hospital of Sichuan University
RECRUITING

Chengdu, China

Contact
Zhejiang Provincial Cancer Hospital
RECRUITING

Hangzhou, China

Contact

Conditions

Explore the condition pages connected to this study.

NTRK NTRK FUSION POSITIVE NTRK FUSION POSITIVE NTRK GENE FUSION NTRK GENE FUSION SOLID TUMORS HARBORING NTRK FUSION